Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565655 | 0.84 | HSPA5 (0.52) | HSPA5NPC1RAB9ALMNACYP1A2 | |
| SCHEMBL1565038 | 0.83 | RAB9A (0.54) | HSPA5NPC1RAB9AADRB2MAPT | |
| SCHEMBL1565298 | 0.82 | NPC1 (0.56) | HSPA5NPC1RAB9ALMNACYP1A2 | |
| SCHEMBL2653915 | 0.81 | SMN1; SMN2 (0.39) | HSPA5NPC1RAB9AADRB2MAPT | |
| SCHEMBL1565548 | 0.80 | HSPA5 (0.49) | HSPA5NPC1RAB9ALMNACYP1A2 | |
| SCHEMBL1565421 | 0.80 | HSPA5 (0.48) | HSPA5NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL1564907 | 0.79 | TP53 (0.55) | HSPA5NPC1RAB9AMAPTLMNA | |
| SCHEMBL1565568 | 0.79 | NPC1 (0.55) | HSPA5NPC1RAB9ALMNACYP1A2 | |
| SCHEMBL1564965 | 0.78 | FFAR2 (0.54) | HSPA5MAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL1566465 | 0.78 | CYP1A2 (0.55) | HSPA5NPC1RAB9ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | claimed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | claimed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | HSPA5 3181/4885NPC1 271/4885RAB9A 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.